Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atazanavir vs Nelfinavir in HIV-Infected Subjects Failing Non-PI Regimens
NCT00028067Phase 3Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2001
- Primary completion
- Apr 2002
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial of atazanavir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Reduction in Viral Load at 48 weeks. Started Aug 2001; status: terminated.
02
Drugs
atazanavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00028067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00028067.